These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Decursin and decursinol angelate inhibit VEGF-induced angiogenesis via suppression of the VEGFR-2-signaling pathway. Jung MH; Lee SH; Ahn EM; Lee YM Carcinogenesis; 2009 Apr; 30(4):655-61. PubMed ID: 19228635 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of vascular endothelial growth factor-induced angiogenesis by scopoletin through interrupting the autophosphorylation of VEGF receptor 2 and its downstream signaling pathways. Pan R; Dai Y; Gao XH; Lu D; Xia YF Vascul Pharmacol; 2011; 54(1-2):18-28. PubMed ID: 21078410 [TBL] [Abstract][Full Text] [Related]
4. Tetraiodothyroacetic acid, a small molecule integrin ligand, blocks angiogenesis induced by vascular endothelial growth factor and basic fibroblast growth factor. Mousa SA; Bergh JJ; Dier E; Rebbaa A; O'Connor LJ; Yalcin M; Aljada A; Dyskin E; Davis FB; Lin HY; Davis PJ Angiogenesis; 2008; 11(2):183-90. PubMed ID: 18080776 [TBL] [Abstract][Full Text] [Related]
5. Ganglioside GM3 inhibits VEGF/VEGFR-2-mediated angiogenesis: direct interaction of GM3 with VEGFR-2. Chung TW; Kim SJ; Choi HJ; Kim KJ; Kim MJ; Kim SH; Lee HJ; Ko JH; Lee YC; Suzuki A; Kim CH Glycobiology; 2009 Mar; 19(3):229-39. PubMed ID: 18974200 [TBL] [Abstract][Full Text] [Related]
6. Lebectin, a Macrovipera lebetina venom-derived C-type lectin, inhibits angiogenesis both in vitro and in vivo. Pilorget A; Conesa M; Sarray S; Michaud-Levesque J; Daoud S; Kim KS; Demeule M; Marvaldi J; El Ayeb M; Marrakchi N; Béliveau R; Luis J J Cell Physiol; 2007 May; 211(2):307-15. PubMed ID: 17323383 [TBL] [Abstract][Full Text] [Related]
7. A novel compound, NP-184, inhibits the vascular endothelial growth factor induced angiogenesis. Lin KT; Lien JC; Chung CH; Kuo SC; Huang TF Eur J Pharmacol; 2010 Mar; 630(1-3):53-60. PubMed ID: 20067787 [TBL] [Abstract][Full Text] [Related]
8. Isoliquiritigenin from licorice root suppressed neovascularisation in experimental ocular angiogenesis models. Jhanji V; Liu H; Law K; Lee VY; Huang SF; Pang CP; Yam GH Br J Ophthalmol; 2011 Sep; 95(9):1309-15. PubMed ID: 21719569 [TBL] [Abstract][Full Text] [Related]
10. VGA1155, a novel binding antagonist of VEGF, inhibits angiogenesis in vitro and in vivo. Ueda Y; Yamagishi T; Ikeya H; Hirayama N; Itokawa T; Aozuka Y; Samata K; Nakaike S; Tanaka M; Ono M; Saiki I Anticancer Res; 2004; 24(5A):3009-17. PubMed ID: 15517909 [TBL] [Abstract][Full Text] [Related]
12. Endothelial cell response to lactate: implication of PAR modification of VEGF. Kumar VB; Viji RI; Kiran MS; Sudhakaran PR J Cell Physiol; 2007 May; 211(2):477-85. PubMed ID: 17167776 [TBL] [Abstract][Full Text] [Related]
13. Anti-angiogenic function of tocotrienol. Miyazawa T; Shibata A; Nakagawa K; Tsuzuki T Asia Pac J Clin Nutr; 2008; 17 Suppl 1():253-6. PubMed ID: 18296349 [TBL] [Abstract][Full Text] [Related]
14. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Roccaro AM; Hideshima T; Raje N; Kumar S; Ishitsuka K; Yasui H; Shiraishi N; Ribatti D; Nico B; Vacca A; Dammacco F; Richardson PG; Anderson KC Cancer Res; 2006 Jan; 66(1):184-91. PubMed ID: 16397231 [TBL] [Abstract][Full Text] [Related]
15. Modulating the hypoxia-inducible factor signaling pathway as a therapeutic modality to regulate retinal angiogenesis. DeNiro M; Alsmadi O; Al-Mohanna F Exp Eye Res; 2009 Nov; 89(5):700-17. PubMed ID: 19580810 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of the tyrosine phosphatase SHP-2 suppresses angiogenesis in vitro and in vivo. Mannell H; Hellwig N; Gloe T; Plank C; Sohn HY; Groesser L; Walzog B; Pohl U; Krotz F J Vasc Res; 2008; 45(2):153-63. PubMed ID: 17962719 [TBL] [Abstract][Full Text] [Related]
17. Natural antioxidant pedicularioside G inhibits angiogenesis and tumourigenesis in vitro and in vivo. Mu P; Gao X; Jia ZJ; Zheng RL Basic Clin Pharmacol Toxicol; 2008 Jan; 102(1):30-4. PubMed ID: 17973903 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy. Wood JM Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930 [TBL] [Abstract][Full Text] [Related]
19. Activation of fractalkine/CX3CR1 by vascular endothelial cells induces angiogenesis through VEGF-A/KDR and reverses hindlimb ischaemia. Ryu J; Lee CW; Hong KH; Shin JA; Lim SH; Park CS; Shim J; Nam KB; Choi KJ; Kim YH; Han KH Cardiovasc Res; 2008 May; 78(2):333-40. PubMed ID: 18006432 [TBL] [Abstract][Full Text] [Related]
20. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584. Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]